Shortly after floating a contingency plan for its asset, vilobelimab—which boasts an emergency use authorization (EUA) for COVID-19 in the U.S.—Germany’s InflaRx is drafting bigger changes to its ...
First AI-driven competitor asset medical activity and scientific narrative tracking platform Built for launch excellence, new asset and indication peri-launch planning Provides reliable competitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results